Boehringer Ingelheim’s Ofev (nintedanib) Receives Health Canada’s Approval as the First Therapy to Treat SSc-ILD in Canada

 Boehringer Ingelheim’s Ofev (nintedanib) Receives Health Canada’s Approval as the First Therapy to Treat SSc-ILD in Canada

Boehringer Ingelheim’s Ofev (nintedanib) Receives Health Canada’s Approval as the First Therapy to Treat SSc-ILD in Canada

Shots:

  • Health Canada approved Ofev (nintedanib) as the first and only treatment, indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease
  • The approval is based P-III SENSCIS study assessing Ofev vs PBO in 576 patients with SSc-ILD across 32 countries including Canada, resulted in slowing loss of pulmonary function by 44% as measured by FVC over 52wks.
  • Ofev is a tyrosine kinase inhibitor, currently approved in 70+ countries including Canada for patients with idiopathic pulmonary fibrosis (IPF) and received FDA’s for approval for treating SSc-ILD

Click here to­ read full press release/ article | Ref: Newswire Canada | Image: Top Employers Institute

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post